Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2001

View Archived Issues

Hemosol provides update on company progress

FDA review period for Remodulin NDA extended

Novazyme's MPS I therapy receives orphan drug designation

ISAtx-247 entering or soon to enter phase II trials for several indications

SIGA Technologies reaches milestone in novel antiinfective agent alliance with Wyeth-Ayerst

Cell Genesys commences phase I/II trial of high-potency GVAX

Clinical evaluation of antiarrhythmic agent RSD-1235 begun by Nortran

Promising efficacy and safety profile reported for DMP-450 at 24 weeks in ongoing phase I/II trial

Potent anti-RSV compound R-170591 characterized at Antiviral Research meeting

Newly synthesized PDE5 inhibitor is more potent and selective than sildenafil

First patient dosed in pivotal trial of Onyx LES for aneurysms

Lipid-lowering effects of FPFS-410 characterized in animal studies

Idun and Abbott extend anticancer alliance for additional year

Phase III trial begins for Atrix acne therapy

Apligraf marketing application submitted to EMEA

Novel antioxidant A-2757 effective in animal models of hepatic and renal injury

DAB-1059, an inhibitor of EGF receptor tyrosine kinase with nanomolar potency and antitumor activity

Italian researchers discover new taxane derivative with antiangiogenic properties

Antiangiogenic and antitumor effects demonstrated in mice for new VEGF RTK inhibitor AG-13925

Promising preclinical findings support further development of Zorex for herpesvirus infections

Antitumor agent with excellent oral activity revealed by Daiichi at recent Japanese meeting

Pharmacological characterization of the potential new prokinetic drug KF-66854

Heterocyclic PGI2 agonists in the Fujisawa pipeline

Boehringer Ingelheim claims indolinone kinase inhibitors with antiproliferative activity

Novel antitumor agent produced by Streptomyces

Chugai presents new antiandrogenic agents useful in prostate cancer, etc.

Triterpenes with ACAT-inhibitory activity designed at Pola

Mitochondrial function activators under development at Takeda

Inhibitors of sPLA2 described in recent patent literature by Shionogi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...